What Is US AAA Screening and Who Qualifies for It?

AAA screening is a one-time abdominal ultrasound that checks whether the body’s largest artery, the aorta, has ballooned to a dangerous size. In the United States, the U.S. Preventive Services Task Force recommends this screening primarily for men aged 65 to 75 who have ever smoked, though the guidelines carve out different recommendations for nonsmoking men, women, and people with a family history of the condition. The whole test takes about ten minutes, involves no radiation, and has strong trial evidence behind it, yet fewer than one in a hundred eligible Medicare beneficiaries actually get it done.

What the Screening Actually Involves

An abdominal aortic aneurysm is a bulge in the lower portion of the aorta, the large blood vessel that runs from the heart down through the abdomen. A normal aorta in that region measures roughly 2 centimeters across. When the wall weakens and the diameter stretches beyond 3 centimeters, it meets the clinical definition of an aneurysm. The danger is rupture: if the aneurysm bursts, internal bleeding is so severe that most people die before reaching a hospital.

The screening itself is a standard abdominal ultrasound. A technician applies gel to your belly and moves a handheld probe over the area while watching measurements on a screen. No needles, no contrast dye, no fasting in most protocols. Ultrasound tends to read slightly smaller than a CT scan for the same aorta, but the difference is small and consistent enough that ultrasound remains the go-to tool for population-level screening.¹ Physical exams, by contrast, miss too many aneurysms to serve as a reliable alternative. A review of the evidence found that abdominal palpation catches only about two-thirds of existing aneurysms, with accuracy dropping further in people who carry more abdominal weight.²

Who Qualifies Under Current Guidelines

The USPSTF, which sets the benchmark for preventive screening in the U.S., divides its AAA recommendations into four groups based on sex, age, and smoking history.³

• Men 65–75 who have ever smoked: Recommended for a one-time ultrasound screening (grade B, meaning there is high certainty of moderate net benefit). “Ever smoked” includes anyone who has smoked at least 100 cigarettes in their lifetime, even decades ago.
• Men 65–75 who have never smoked: Clinicians should selectively offer screening based on other risk factors such as family history or cardiovascular disease, rather than screening everyone in this group (grade C).
• Women who have never smoked and have no family history: Routine screening is recommended against (grade D), because the condition is rare enough in this group that the harms of testing outweigh any benefit.
• Women 65–75 who have ever smoked or have a family history: The evidence is considered insufficient to make a firm call either way (grade I). The Task Force neither recommends nor discourages screening for these women, leaving the decision to patients and clinicians.

Smoking dominates these guidelines because tobacco use is the single strongest modifiable risk factor for AAA. The chemicals in cigarette smoke damage the aortic wall through multiple pathways: they ramp up inflammation, weaken the smooth muscle cells that give the artery its structure, and degrade the connective tissue matrix that holds everything together.⁴ Enzymes called matrix metalloproteinases, which break down structural proteins in the vessel wall, play a central role in how aneurysms form and grow.⁵

Family History as a Risk Factor

Even if you have never smoked, having a close relative with an AAA substantially raises your own risk. One study that screened siblings of AAA patients found that about 11% of brothers had an aneurysm, compared with roughly 1.5% of men in the control group. After adjusting for age and sex, family history increased the risk more than fourfold.⁶ A larger investigation of over 500 AAA patients’ families found that nearly a quarter had at least one affected relative. Female relatives of AAA patients faced a particularly elevated risk compared with the general female population, and the risk was highest among relatives of women who had the condition.⁷

This is one reason the USPSTF’s grade-C recommendation for nonsmoking men and the grade-I statement for certain women both hinge partly on family history. If your father, mother, or sibling had an AAA, the conversation with your doctor about screening becomes more urgent regardless of your smoking status.

Why the Screening Gap for Women Is Controversial

AAA has traditionally been viewed as a condition that overwhelmingly affects men, and the screening guidelines reflect that. Women develop aneurysms at lower rates, partly because estrogen appears to protect the aortic wall from the inflammatory processes that drive aneurysm formation. But once an aneurysm does develop in a woman, the picture is worse in almost every way: aneurysms in women tend to expand faster, rupture at smaller diameters, and carry higher mortality after rupture.⁸ Registry data also show that women face higher odds of dying after elective AAA repair compared with men.⁹

The USPSTF’s “insufficient evidence” label for women who smoke or have a family history is not the same as saying screening is useless for them. It means the existing randomized trials, which enrolled almost exclusively men, simply have not generated enough data on women to measure the trade-off between benefits and harms. Recent cost-effectiveness analyses have begun to suggest that screening women who smoke may be worth the expense, particularly when combined with genetic risk scores to better target who gets tested.¹⁰ For now, the decision for women in higher-risk categories remains a shared one between patient and doctor.

The Evidence That Screening Saves Lives

The case for screening men rests on four large randomized trials conducted over the past few decades, the most prominent being the British Multicentre Aneurysm Screening Study (MASS). Over 13 years of follow-up, the group of men invited to screening had 42% fewer AAA-related deaths than the uninvited group. The benefit grew steadily over time and translated into a modest but real reduction in overall mortality as well. Researchers estimated that roughly 216 men needed to be invited to screening to prevent one AAA death over that period.¹¹

A systematic review and meta-analysis pooling results across trials confirmed these patterns: screening significantly reduced AAA-related deaths and cut the rate of emergency aneurysm repair, while increasing the rate of planned elective repairs.¹² A separate meta-analysis found a similar story: emergency operations dropped by roughly half in screened groups, though elective surgery rates went up by about threefold, since screening catches aneurysms that would otherwise go unnoticed until they become emergencies.¹³ That trade-off, fewer emergencies in exchange for more planned surgeries, is central to the screening debate.

Potential Harms and Overdiagnosis

No screening test is purely beneficial. AAA screening can detect small aneurysms that may never have ruptured or caused symptoms during a person’s remaining lifetime, which means some people end up in years of surveillance imaging or even undergo surgery they did not strictly need. A Swedish registry study estimated that for every 10,000 men offered screening, about 49 were likely to be overdiagnosed, meaning their aneurysm would not have harmed them. Of those 49, roughly 19 went on to have surgery that exposed them to operative risks without a clear personal payoff.¹⁴

There is also the anxiety that comes with knowing you have a ticking time bomb in your abdomen, even if it is small and may never need treatment. For most men in the target population, the mortality benefit of screening outweighs these harms, but it is worth understanding that the calculus is not one-sided.

Medicare Coverage and the Underutilization Problem

Medicare has covered a one-time AAA screening ultrasound since 2007 under the Screening Abdominal Aortic Aneurysms Very Efficiently (SAAAVE) Act. The benefit is available as part of the “Welcome to Medicare” preventive visit and covers men who have ever smoked, plus men and women with a family history of AAA.¹⁵ In practical terms, the test is free at the point of care for eligible beneficiaries if ordered during that initial Medicare visit.

Despite the coverage, uptake has been remarkably low. Medicare data have consistently shown that fewer than 1% of eligible people actually get screened.¹⁶ An analysis of claims data after the SAAAVE Act took effect found that fewer than 3% of all abdominal ultrasound claims were for the specific AAA screening benefit. While the act did bump up ultrasound use among 65-year-old men by a couple of percentage points, this increase was not associated with measurable changes in rates of AAA repair, rupture, or death at the population level.¹⁷ The reasons for underuse likely include the fact that many eligible men never schedule the Welcome to Medicare visit in the first place, that primary care doctors may not think to order the screening, and that the one-time window at age 65 is easy to miss.

What Happens if an Aneurysm Is Found

If the screening ultrasound shows a normal aorta (under 3 cm), you are done. No follow-up imaging is needed. If it reveals an aneurysm, the next step depends entirely on the size.

Small aneurysms (roughly 3 to 4.9 cm) are not repaired immediately. Instead, they are monitored with periodic ultrasounds, typically every 12 months for aneurysms in the 4 to 4.9 cm range, with intervals stretched longer for smaller ones.¹⁸ During this surveillance phase, the focus is on controlling cardiovascular risk factors. Quitting smoking is the most important step, since continued tobacco use is linked to faster aneurysm growth.¹⁹ Observational studies have suggested that statins may slow expansion by as much as half, though randomized trials specifically testing this have not been conducted, so it remains unclear whether the effect is from the drug itself or from other factors associated with statin use.²⁰ A randomized trial of telmisartan, a blood pressure medication that was thought to have vessel-protective properties, found no effect on AAA growth rate compared with placebo.²¹ In short, there is currently no proven drug therapy to shrink or halt an aneurysm. Surveillance and risk-factor control are the mainstays.

When Repair Becomes Necessary

International guidelines have long used 5.5 cm as the threshold at which elective repair is recommended for men. Below that size, the annual risk of rupture is low enough that operating would expose the patient to surgical risk without a clear survival benefit. The mortality rate from planned open surgical repair runs around 3%, and the 5.5 cm cutoff is the diameter at which the expected rupture risk begins to outpace that operative mortality.²²

For women, there is growing discussion about whether a lower threshold is warranted, since their aneurysms tend to rupture at smaller diameters. Modeling work has suggested that the optimal repair size may differ substantially between men and women: one analysis found that for an average-health 60-year-old woman, the best threshold to minimize AAA-related death was about 6.1 cm, while for a man of the same age and health it was about 6.9 cm, both higher than the traditional 5.5 cm guideline.²³ These numbers are model outputs, not clinical consensus, and the field is still debating whether and how to adjust thresholds for sex. Swedish registry data on women who received elective repair at smaller diameters (4.9 to 5.4 cm) versus the standard threshold are adding real-world evidence to this conversation.²⁴

Open Surgery Versus Endovascular Repair

When an aneurysm reaches the repair threshold, two surgical approaches are available. Open repair involves a large abdominal incision, clamping the aorta, and sewing in a synthetic graft. Endovascular repair (EVAR) threads a stent graft through the femoral arteries in the groin and deploys it inside the aneurysm, avoiding a major incision entirely.

EVAR is the less invasive option and dominates in the short term. A 12-year retrospective comparison found that EVAR cut operative time roughly in half, reduced blood loss dramatically, and shortened hospital stays from a median of nine days to five. Thirty-day mortality was about 1% for EVAR versus roughly 3% for open repair.²⁵ The trade-off is durability: EVAR patients tend to need more follow-up procedures over the years because stent grafts can develop leaks or shift out of position. That same study found more late aneurysm-related complications in the EVAR group, though the combined rate of all late complications was similar between the two approaches.

The long-term survival picture is muddier than you might expect. A large randomized trial followed patients for up to 15 years and found no significant difference in overall survival between EVAR and open repair.²⁶ A Medicare database study using matched patients actually found that open repair was associated with lower long-term mortality, fewer ruptures, and fewer reinterventions over six years, though it came with significantly higher 30-day mortality and more perioperative complications including heart attack, respiratory problems, and intestinal ischemia.²⁷ The upshot is that the choice between EVAR and open repair depends heavily on the individual patient’s age, fitness, and ability to tolerate a major operation. Younger, healthier patients may benefit from the long-term durability of open repair despite its harder recovery. Older or sicker patients often do better with EVAR because surviving the perioperative period is the more immediate concern.

Cost-Effectiveness and the Economic Argument

One-time ultrasound screening for men aged 65 and older has consistently been shown to be cost-effective by the standards used in health-care economics. The MASS trial’s 10-year data put the cost at about £100 per man invited, translating to roughly £7,600 per life year gained, a figure well below the thresholds most health systems consider acceptable.²⁸ A U.S.-specific modeling analysis similarly concluded that screening men starting at 65 is both effective and cost-effective for preventing AAA-related deaths.²⁹

For women, the economics are less favorable when applied to the general female population, but improve substantially when screening is targeted to women who smoke. One analysis found that screening women smokers produced the most favorable cost-effectiveness ratio at around $24,000 per quality-adjusted life year, and that adding polygenic risk scores to further narrow the target group improved the numbers even more.¹⁰ These findings are fueling calls to move toward more risk-stratified screening approaches rather than the current broad demographic categories.

Incidental Findings and What Else the Ultrasound Can Reveal

Because the screening ultrasound scans the abdominal area, it sometimes picks up findings unrelated to the aorta: kidney abnormalities, gallstones, liver masses, and other conditions that were not the reason for the test. This is a double-edged reality. On one hand, incidental findings can occasionally lead to early detection of something important. On the other, they can trigger additional imaging, biopsies, and anxiety over conditions that turn out to be harmless. The possibility of clinically significant incidental findings is recognized as both a potential benefit and a complication of AAA screening programs.³⁰ If you are going in for an AAA screen, it is worth knowing that the ultrasound could surface something unexpected, and that additional workup may follow even if your aorta looks fine.

Screening Impact on Repair Rates in Underserved Groups

One lingering question is whether the guideline expansions over the years, particularly the 2014 addition of nonsmoking men and the softer stance on women who smoke, have actually changed clinical outcomes. A study examining national repair data found that AAA repair rates among male nonsmokers aged 65 to 75 did not significantly change after the guidelines were updated. Among female smokers in the same age range, there was likewise no meaningful shift in repairs.³¹ When the researchers narrowed the analysis to male nonsmokers on Medicare, they did find a modest relative increase of about 10% in the proportion undergoing repair, but the absolute numbers were small. The broader takeaway is that guidelines alone do not change practice if patients and providers are not aware of them, and the chronic underutilization of the Medicare screening benefit underscores this gap.